Stock comparison
LeMaitre Vascular
Regeneron Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
REGN
Regeneron Pharmaceuticals
Market cap
$65.82B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | REGN | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 64C | LMAT |
| Benjamin Graham | 89A | 68B | LMAT |
| Philip Fisher | 81C | 48D | LMAT |
| Peter Lynch | 67B | 26F | LMAT |
| Joel Greenblatt | 56D | 45D | LMAT |
| Charlie Munger | 68D | 59C | LMAT |
| Terry Smith | 69D | 57C | LMAT |
Side-by-side metrics
| Metric | LMAT | REGN |
|---|---|---|
| Market cap | $2.23B | $65.82B |
| P/E (TTM) | 37.1x | 16.4x |
| EV/EBIT | 36.6x | 20.0x |
| ROIC (TTM) | 9.43% | 8.53% |
| Gross margin | 72.39% | 84.55% |
| Net margin | 24.35% | 29.65% |
| Revenue CAGR 5y | 12.75% | -2.81% |
| EPS CAGR 5y | 19.04% | -13.35% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.84% | 0.51% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- EPS CAGR 5y19.04%vs -13.35%+170%
- Revenue CAGR 5y12.75%vs -2.81%+122%
- Dividend yield0.84%vs 0.51%+39%
- ROIC (TTM)9.43%vs 8.53%+10%
REGN leads on
- Market cap$65.82Bvs $2.23B+97%
- Debt / Equity0.1xvs 0.5x+82%
- P/E (TTM)16.4xvs 37.1x+56%
- EV/EBIT20.0xvs 36.6x+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.